secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2024-09-20T23:59:59+00:00
Accession:  0001628280-24-040982
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex appoints Ozan Pamir as CFO effective October 21, 2024; James Lee returns to Controller role
--------------------------------------------------------------------------------

- Ozan Pamir named CFO effective Oct 21; succeeds interim CFO James Lee who remains Controller.
- Annual base salary of $400,000; target bonus 50% of base; option grant with initial value of $360,000.
- Pamir previously CFO of 180 Life Sciences; also held investment banking roles at Ventum Financial.
- Option vests: 1/3 one-year anniversary, rest over 24 months; severance: 9 months' base salary on termination without cause.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/0001628280-24-040982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024040982/cdxc-20240919.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-040982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer